Challenges in diabetes mellitus type 2 management in Nepal: a literature review by Gyawali, Bishal et al.
  
Bishal Gyawali, Alessandra Ferrario, Edwin van Teijlingen 
and Per Kallestrup 
Challenges in diabetes mellitus type 2 
management in Nepal: a literature review 
 
Article (Published version) 
(Refereed) 
 
Original citation: Gyawali, Bishal, Ferrario, Alessandra, van Teijlingen, Edwin and Kallestrup, 
Per (2016) Challenges in diabetes mellitus type 2 management in Nepal: a literature review. Global 
Health Action, 9 . ISSN 1654-9716 
DOI: 10.3402/gha.v9.31704 
 
 
Reuse of this item is permitted through licensing under the Creative Commons: 
© 2016 The Authors 
CC BY 4.0 
 
This version available at: http://eprints.lse.ac.uk/68799/ 
Available in LSE Research Online: January 2017 
 
LSE has developed LSE Research Online so that users may access research output of the School. 
Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or 
other copyright owners. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE Research 
Online website.  
 
 
 
REVIEW ARTICLE
Challenges in diabetes mellitus type 2 management in
Nepal: a literature review
Bishal Gyawali1,2*, Alessandra Ferrario3, Edwin van Teijlingen4 and
Per Kallestrup1
1Center for Global Health, Department of Public Health, Aarhus University, Aarhus, Denmark; 2Nepal
Development Society (NEDS), Bharatpur, Nepal; 3LSE Health, London School of Economics and Political
Science, London, United Kingdom; 4Faculty of Health & Social Sciences, Bournemouth University, Dorset,
United Kingdom
Background and objectives: Diabetes has become an increasingly prevalent and severe public health problem
in Nepal. The Nepalese health system is struggling to deliver comprehensive, quality treatment and services
for diabetes at all levels of health care. This study aims to review evidence on the prevalence, cost and
treatment of diabetes mellitus type 2 and its complications in Nepal and to critically assess the challenges to
be addressed to contain the epidemic and its negative economic impact.
Design: A comprehensive review of available evidence and data sources on prevalence, risk factors, cost,
complications, treatment, and management of diabetes mellitus type 2 in Nepal was conducted through an
online database search for articles published in English between January 2000 and November 2015. Additionally,
we performed a manual search of articles and reference lists of published articles for additional references.
Results: Diabetes mellitus type 2 is emerging as a major health care problem in Nepal, with rising prevalence
and its complications especially in urban populations. Several challenges in diabetes management were
identified, including high cost of treatment, limited health care facilities, and lack of disease awareness among
patients. No specific guideline was identified for the prevention and treatment of diabetes in Nepal.
Conclusions: We conclude that a comprehensive national effort is needed to stem the tide of the growing
burden of diabetes mellitus type 2 and its complications in Nepal. The government should develop a
comprehensive plan to tackle diabetes and other non-communicable diseases supported by appropriate health
infrastructure and funding.
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Introduction
Cardiovascular disease, cancer, diabetes, chronic respira-
tory diseases, and other non-communicable diseases
(NCDs) kill more than 36 million people each year and
they are responsible for nearly half of the global burden
of disease (1). In particular, these NCDs are of increasing
concern in low- and middle-income countries (LMICs)
where 80% of all global NCD deaths occur. The World
Health Organization (WHO) projects that the burden of
NCDs will increase rapidly predicting NCD deaths to
increase by 15% globally between 2010 and 2020 (2).
This rising prevalence of NCDs is associated with in-
creasing urbanization, the influence of globalization on
consumption patterns, and an aging population (3).
Importantly, many LMICs will face higher levels of
NCDs at earlier stages of their economic development,
with fewer resources, and with less time to respond
effectively (4). People in LMICs tend to develop disease
at younger ages, suffer longer, and die sooner compared
to high-income countries, which can undermine the eco-
nomic development of these countries. Diabetes is emer-
ging as a major global problem worldwide and is reaching
epidemic proportions with global prevalence of 8.3%,
affecting 387 million adults and costing 612 billion
dollars in health care spending in 2014 (5).
In 2013 Nepal had one of the lowest gross domestic
products (GDPs) per capita at US$ 1,500 (6). Its eco-
nomy is characterized by low productivity and growth,
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making the country heavily dependent on external aid.
The total population of Nepal is nearly 27 million with
an annual growth rate of 1.6% (7), of which 17% live in
cities. Currently, Nepal is the fastest urbanizing country
in South Asia (4.9% per year) (8). Poverty remains a
serious problem with about a quarter living below the
poverty level of US$ 1.25 per day (9). Although the
proportion of people living in poverty has declined from
42 to 25% over the past 15 years, it still remains high
in the rural settings, where poverty levels are between
1.8 and 10 times higher than in the cities (10). Life
expectancy in Nepal has increased steadily over the past
20 years to 67.9 years for males and 65.5 years for
females (11).
Nepal is experiencing an epidemiological transition
with a prevalence of NCDs estimated to range from 31%
(12) to 36.5% (13). The four most prevalent NCDs are
chronic obstructive pulmonary disease (COPD), cardio-
vascular disease, diabetes, and cancer (12). NCDs were
estimated to account for 60% of all deaths in Nepal in
2014 (14). The projected increase in the burden of NCDs
is largely driven by the globalization and urbanization.
These determinants in turn contribute to the common
chronic disease risk factors of unhealthy diet, inactive
lifestyle, harmful use of alcohol, and tobacco use and
finally increase the chance of developing hypertension,
obesity, and diabetes.
A recent systematic review and meta-analysis showed
a prevalence rate of diabetes mellitus type 2 (DMT2) of
8.4% in Nepal (15). Relative to neighbouring countries
such as Pakistan, Sri Lanka, and Bangladesh, Nepal has
a higher prevalence of DMT2 and impaired glucose
tolerance (16). However, this finding about Nepal should
be handled with caution as no large-scale studies have
been conducted.
The health care system in Nepal is facing several
challenges. Most health care facilities are concentrated
in urban areas while rural health facilities often lack
resources, staff, and infrastructure (17). The country has
one of the world’s most deprived health systems, with
a density of medical doctors, nurses, and midwives of
0.67 per 1,000 population, far less than the WHO’s
benchmark of 2.3 health care professionals per 1,000
population (18). Nepal’s health care deficits are largely
attributed to low government spending, unevenly dis-
tributed health services, limited affordability, inadequate
supply of essential drugs, low awareness of disease and
possible treatment, and poor retention of human re-
sources in rural areas (19). Nepal spends only 6% of its
GDP on health care (20). Of this, most of the expenditure
(about 70%) is private out-of-pocket (21). In view of this
high share of out-of-pocket expenditure on health care,
the Government of Nepal is working towards universal
health coverage in line with the Sustainable Development
Goals (SDGs) to provide: 1) universal access to basic
health services, and 2) free essential drugs and diagnostics
as part of the New National Health Policy (22). Nepal
initiated a free essential health care services (EHCS)
programme in 2007, which included a limited range of
free care services in the publicly funded primary health
care and secondary health care with a limited number of
free essential medicines (23).
Treatment and management of diabetes is a major chal-
lenge in Nepal, for reasons such as low disease awareness
among the population; various socio-cultural factors;
educational strategies; and paucity of programmes to
detect, manage, and prevent diabetes and its complica-
tions (15). Health care professionals and policymakers
have to come together to assess the increasing burden of
diabetes and design appropriate preventive and manage-
ment strategies. This study aims to review evidence on the
prevalence of DMT2 and its complications, the cost,
treatment, and challenges to be addressed to contain the
epidemic and its negative economic consequences. To
our knowledge, no such study has been carried out. This
literature review critically assesses the evidence, and
will make recommendations to help improve diabetes
management in Nepal.
Methods
A review of available evidence was conducted on PubMed
on DMT2 and complications, its associated cost, expen-
diture, treatment, and prevention in Nepal. We performed
a manual search for other articles and additional references
from published articles through Google. We also included
reports and articles from the WHO (24, 25), the Interna-
tional Diabetes Federation (IDF) (16), the Government of
Nepal (2628), and a conference presentation (29).
A search of the online databases for studies published in
English was performed using the keywords: ((‘diabetes’
[Title/Abstract] AND ‘NEPAL’ [Title/Abstract])) OR
((‘Diabetes Mellitus’ [Mesh] OR ‘Diabetes Mellitus, Type
2’ [Mesh] AND ‘NEPAL’ [Mesh])) in PubMed. To ensure
the most current and relevant studies, the search was
limited to studies published between January 2000 and
November 2015. The search was conducted in December
2015. Studies presenting evidence on prevalence, costs,
complications, treatment, and prevention were included in
the analysis. Studies published in languages other than
English were excluded. We also consulted with national
NCD experts during literature gathering. If costs datawere
reported only in Nepalese Rupee (NPR), we converted the
amounts into United States dollar (US$).
Results
The search strategy yielded 88 papers in PubMed. Then
duplicates (n5) and irrelevant papers based on title
(n54) were excluded and seven were excluded after
reading the abstract. A further five additional peer-reviewed
Bishal Gyawali et al.
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papers were identified through Google and seven were
identified through reference searching including grey
literature and presentations, leaving a total of 34 papers
for analysis (Fig. 1). International studies, national surveys,
and small cross-sectional surveys on DMT2 in Nepal
were included (Table 1). Table 2 summarizes the relevant
literature on DMT2.
Prevalence of DMT2 and its complications
Prevalence
The IDF estimates that the prevalence of DMT2 in Nepal
was 4.5% in 2012 and the predicted number of undiag-
nosed cases in adults was 294 per 1,000 population (16).
Various cross-sectional studies reported prevalence of
DMT2 in different settings. A study by Shrestha et al. in
2006 reported a prevalence of 19% of DMT2 in urban
Nepal (35). This study also reported that 54.4% (53.8%
of men and 55.1% of women) were undiagnosed (35),
similar to rates reported elsewhere (32, 36, 37). Compared
to rural prevalence, the urban one is high (14.6% of
DMT2 among city dwellers in 2003) (32). This study
reported a rural prevalence of 2.5%. Yet in a rural study
in Nepal, Sasaki et al. reported a much lower prevalence
of 0.3% in 2004 (34). Studies reporting prevalence in
rural areas show consistently lower prevalence estimates
than those studies reporting urban prevalence. Caution is
however needed when interpreting the results due to
different methodologies applied.
Risk factors
Studies reported non-modifiable risk factors for DMT2
including increased age (31, 35, 44), being a woman
(32, 35, 36, 44) and altered immunity (38) and several
modifiable risk factors such as urban residency (36),
higher socio-economic status (36), higher body mass
index (BMI) (36), lack of physical activity (44, 51), low
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Fig. 1. Flow chart of the study selection process.
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Table 1. List of articles included in the analysis
Author Title
Publication
year Reference
Baral et al. Evaluation of new WHO diagnostic criteria for diabetes on the prevalence of
abnormal glucose tolerance in a heterogeneous Nepali population  the implications
of measuring glycated hemoglobin
2000 (30)
Karki et al. Prevalence of non-insulin dependent diabetes mellitus in urban areas of eastern
Nepal: a hospital based study
2000 (31)
Singh and Bhattarai High prevalence of diabetes and impaired fasting glycaemia in urban Nepal 2003 (32)
Jha Cost analysis for management of type-2 diabetes: a case study of rural and urban
setting
2004 (33)
Sasaki et al. The prevalence of diabetes mellitus and impaired fasting glucose/glycaemia (IFG) in
suburban and rural Nepal-the communities-based cross-sectional study during the
democratic movements in 1990
2005 (34)
Shrestha et al. The prevalence of hypertension and diabetes defined by fasting and 2-h plasma
glucose criteria in urban Nepal
2006 (35)
Mehta et al. Risk factors, associated health problems, reasons for admission and knowledge
profile of diabetes patients admitted in BPKIHS
2006 (36)
Ono et al. The prevalence of type 2 diabetes mellitus and impaired fasting glucose in semi-
urban population of Nepal
2007 (37)
Kart et al. Lay explanations and self-management of diabetes in Kathmandu, Nepal 2007 (38)
Upadhyay et al. Prescribing pattern in diabetic outpatients in a tertiary care teaching hospital in Nepal 2007 (39)
Shrestha et al. Prevalence of and factors associated with diabetic retinopathy among diabetics in
Nepal: a hospital based study
2007 (40)
Upadhyay et al. Knowledge, attitude and practice about diabetes among diabetes patients in
western Nepal
2008 (41)
Paudyal et al. Prevalence of diabetic retinopathy following a community screening for diabetes 2008 (42)
Chettri and Chapman Prevalence and determinants of diabetes among the elderly population in the
Kathmandu Valley of Nepal
2009 (43)
Rajbhandari Diabetes in Nepal-future and perspective 2010 (29)
Mehta et al. Hyperglycemia, glucose intolerance, hypertension and socioeconomic position in
eastern Nepal
2011 (36)
Sharma et al. Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal 2011 (44)
Thapa et al. Demographics and awareness of diabetic retinopathy among diabetic patients
attending the vitreo-retinal service at a tertiary eye care center in Nepal
2012 (45)
International Diabetes
Federation
IDF Diabetes Atlas: country estimates table 2011 2012 (16)
Sharma et al. Community-based screening for chronic kidney disease, hypertension and diabetes
in Dharan
2013 (46)
Shrestha et al. Cost of diabetes mellitus care among patients attending selected outpatient clinics 2013 (47)
Government of Nepal Multisectoral action plan for the prevention and control of non-communicable
diseases (20142020)
2013 (26)
Prasai A review of studies on Nepal’s national free health care programme 2013 (28)
Parajuli et al. Factors associated with nonadherence to diet and physical activity among Nepalese
type 2 diabetes patients; a cross sectional study
2014 (48)
Saito et al. Catastrophic household expenditure on health in Nepal: a cross-sectional survey 2014 (25)
Aryal et al. Non communicable diseases risk factors: STEPS Survey Nepal 2013 2014 (24)
Poudel Government expands essential drugs list, focus shifts to non-communicable
diseases
2014 (49)
Poudel Diabetes and endocrinology in Nepal 2014 (50)
Gautam et al. Diabetes related health knowledge, attitude and practice among diabetic patients in
Nepal
2015 (51)
Maskey et al. Hypothyroidism in diabetes mellitus patients in Eastern Nepal 2015 (52)
Bishal Gyawali et al.
4
(page number not for citation purpose)
Citation: Glob Health Action 2016, 9: 31704 - http://dx.doi.org/10.3402/gha.v9.31704
education (36), hypertension (35, 36), and disturbed sleep
and family history of hypertension (43). A study to
explore lay explanations and self-management of diabetes
in urban Nepal reported stress or worry, diet or eating
habits, heredity, pollution in the environment, and self-
care behaviour as the main causes of DMT2 (38), while
another institution-based cross-sectional study reported
alcohol and tobacco use as common risk factors for
DMT2 (51).
Diabetes complications
Diabetes can lead to serious complications and is asso-
ciated with a range of comorbidities. The literature sug-
gests that the prevalence of complications and comorbid
diseases in DMT2 patients were retinopathy (19.378%),
hypertension (36.770.6%), other ocular problems (39%),
renal problems (25%), neurological problems (25%), dia-
betic foot (21.4%), depressive symptoms (6.254.1%),
gastritis (8.5%), angina (5.1%), and hypothyroidism
(4.1%) (Table 3). Evidence shows that diabetes complica-
tions can significantly inflate the cost of diabetes in
Nepal. It is reported that the total direct cost per year for
a patient living with diabetes for 1620 years of illness
was approximately 161% higher than for a patient with a
history of DMT2 for 15 years (47).
Diabetes cost
Few hospital-based studies reported evidence on cost of
diabetes in Nepal (Table 4). A study on the cost of 227
diabetic patients at four outpatient private clinics in
Kathmandu was conducted in 2010 (47). The mean total
cost per visit paid out-of-pocket by patients with diabetes
in an outpatient clinic was reported to be US$ 13.3.
The study also reported that the total cost incurred in the
treatment and care of diabetes per month was US$ 40.4
and US$ 445 per annum. Medicinal costs accounted
for the majority (80%) of the total direct cost per
visit (US$ 11). The study concluded that diabetes patients
in the private sector of Nepal experience a high cost
burden.
In LMICs, the cost of prescription drugs can make up
for a substantial proportion of total cost of illness in
many chronic diseases including diabetes. A 2007 study
on demographic profiles and patterns of drug prescribing
among ambulatory patients with diabetes at an urban
outpatient pharmacy (OPP) found that the average cost
per prescription per visit was US$ 16.2 (39). The study
reported a very large variation in cost among trade names
of particular drugs. The study found that anti-diabetic
medications constituted 58.9% of the total cost of
medications. Among the anti-diabetic medication, insulin
was responsible for the highest proportion (41.1%) of
the total cost incurred on anti-diabetics followed by
biguanides (32.6%). A 2002 study, in both rural and
urban Nepal, estimated the median expenditure on
diabetes health care to US$ 76.5 excluding other expenses
of a diabetic patient such as for home blood glucose
monitor, test strips, lancets, urine sticks, blood pressure
measuring equipment, and exercising machines (33).
The study also concluded that diabetes is one of the
most costly and burdensome NCDs on families and on
the health care system.
Table 1 (Continued )
Author Title
Publication
year Reference
Mishra et al. Depression and health-related quality of life among patients with type 2 diabetes
mellitus: a cross-sectional study in Nepal
2015 (53)
Joshi et al. Illness perception and depressive symptoms among persons with type 2 diabetes
mellitus: an analytical cross-sectional study in clinical Settings in Nepal
2015 (54)
Aryal et al. The burden and determinants of non communicable diseases risk factors in Nepal:
findings from a nationwide STEPS survey
2015 (27)
Kalra et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A
consensus statement
2015 (55)
Table 2. Relevant articles on various areas of DMT2
Areas of diabetes management Number of papers References
Prevalence 12 (16, 24, 27, 3032, 34, 3537, 44, 46)
Risk factors 7 (31, 35, 36, 38, 43, 44, 51)
Complications 9 (35, 36, 39, 40, 42, 45, 5254)
Cost 4 (25, 33, 39, 47)
Treatment 5 (26, 33, 41, 49, 55)
Challenges in diabetes management 7 (28, 29, 36, 41, 48, 50, 51)
Challenges in DMT2 management in Nepal
Citation: Glob Health Action 2016, 9: 31704 - http://dx.doi.org/10.3402/gha.v9.31704 5
(page number not for citation purpose)
Table 3. Diabetes-related complications
Estimates Study year Sample frame and sample Study design Diagnostics Reference
Diabetic retinopathy
19.3% 2008 Sample frame: Semi-urban setting
Sample: 34 DMT2 patients
Mean age: 54.7912 years
Community-based
cross-sectional study
Blood samples, ocular
examination
(42)
44.7% 20052006 Sample frame: Tertiary eye care centre
Sample: 371 DMT2 patients
Mean age: 57.4912 years
Hospital-based cross-
sectional study
Blood samples, ocular
examination
(40)
78% 20052006 Sample frame: Tertiary eye care centre
Sample: 210 DMT2 patients
Mean age: 57910.4 years
Hospital-based cross-
sectional study
Blood samples, ocular
examination
(45)
Hypertension
70.6% 2006 Sample frame: outpatient pharmacy
(OPP); urban setting
Sample: 182 DMT2 patients
Mean age: 56.9912.6 years
Cross-sectional study NR (39)
60.7% 20032004 Sample frame: Medical units
Sample: 310 DMT2 patients
60% women, 40% men
Hospital-based
exploratory study
NR (36)
36.7% 20012002 Sample frame: Seven wards of
metropolitan and sub-metropolitan
municipalities
Sample: 105 DMT2 patients
13.2% women, 11.5% men
Field survey Fasting and 2 h plasma glucose,
Blood Pressure measurement
(35)
Renal problem
25% 20032004 Sample frame: Medical units
Sample: 310 DMT2 patients
60% women, 40% men
Hospital-based
exploratory study
NR (36)
Neurological problem
25% 20032004 Sample frame: Medical units
Sample: 310 DMT2 patients
60% women, 40% men
Hospital-based
exploratory study
NR (36)
Other ocular problem
39% 20032004 Sample frame: Medical units
Sample: 310 DMT2 patients
60% women, 40% men
Hospital-based
exploratory study
NR (36)
Diabetes foot
21.4% 20032004 Sample frame: Medical units
Sample: 310 DMT2 patients
60% women, 40% men
Hospital-based
exploratory study
NR (36)
Hypothyroidism
4.1% 20122013 Sample frame: Urban setting
Sample: 271 DMT2 patients
Hospital-based
descriptive study
Thyroid function test (52)
Depressive symptom
54.1% 2014 Sample frame: Tertiary hospital
Sample: 157 DMT2 patients
60.5% women, 39.5% men
Cross-sectional
surveys
PHQ-9 scale (53)
44.1% 20132014 Sample frame: Tertiary hospital
Sample: 379 DMT2 patients
Mean age: 54.8910.7 years
Analytical cross-
sectional study
BDI-II scale (54)
6.2% 2006 Sample frame: OPP; urban setting
Sample: 182 DMT2 patients
Mean age: 56.9912.6
Cross-sectional study NR (39)
Bishal Gyawali et al.
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Health expenditures (including drugs) are largely paid
for out-of-pocket in Nepal. A study conducted in 2011
2012 in Kathmandu provided evidence relating diabetes
illnesses to catastrophic out-of-pocket expenditure on
health care (25). The study reported that more than one
in every seven households experienced catastrophic expen-
diture on health. It concluded that injuries and major
NCDs including diabetes, asthma, and heart disease were
frequently associated with catastrophic spending in the
poorest household.
Treatment
National guidelines for diabetes prevention and treatment
Currently, there is no specific guideline for the prevention
and treatment of DMT2 although the government has
recently spearheaded a Multi-sectoral Action Plan on the
Table 3 (Continued )
Estimates Study year Sample frame and sample Study design Diagnostics Reference
Gastritis
8.5% 2006 Sample frame: OPP; urban setting
Sample: 182 DMT2 patients
Mean age: 56.9912.6
Cross-sectional study NR (39)
Angina
5.1% 2006 Sample frame: OPP; urban setting
Sample: 182 DMT2 patients
Mean age: 56.9912.6
Cross-sectional study NR (39)
NRNot Reported.
Table 4. Cost of diabetes in Nepal
Source of cost
Study
year Study setting Amount (NPR) Amount (US dollar) Reference
Average
cost per
prescription
2006 Sample frame: outpatient pharmacy
(OPP); Urban setting
Sample: 182 DMT2 patients
Study design: cross sectional
1156.2 16.2 (39)
Total cost per
visit
2010 Sample frame: A public hospital, a
private hospital and two polyclinics
one each in Kathmandu and Lalitpur
Sample: 227 DMT2 patients
Study design: cross sectional
NR Mean cost per patient per visit
Public sector: Mean 5.1, SD
253, 95% CI 4.35.9
Private sector: Mean 17.5, SD
948.2, CI 15.49.6
(47)
Total cost per
month
2010 Sample frame: A public hospital, a
private hospital and two polyclinics
one each in Kathmandu and Lalitpur
Sample: 227 DMT2 patients
Study design: cross sectional
NR Mean cost of illness per patient
per month
Mean 40.4, SD 2232.7, 95% CI
36.444.5
(47)
Total cost per
annum
2010 Sample frame: a public hospital, a
private hospital and two polyclinics
one each in Kathmandu and Lalitpur
Sample: 227 DMT2 patients
Study design: cross sectional
NR Mean cost per patient per annum
Mean 445.9, SD 27534.9, 95%
CI 396.1495.6
(47)
Total cost per
annum
2002
2003
Sample frame: Two sites in Dhulikhel
community and Kathmandu’s
Diabetes clinic; rural and urban
setting
Sample: 60 DMT2 patients
Study design: Prospective
observational follow-up
Cost to the health
system and the
patient per annum
5470
NR (33)
NRNot Reported.
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‘Prevention and Control of NCDs 20142020’ to reduce
preventable morbidity, avoidable disability, and prema-
ture mortality as a result of major NCDs (26). The action
plan contains broad strategic actions and key milestones
to be achieved within a specified time frame such as
decreasing the overall mortality of diabetes by 25% and
halting the rise in obesity and diabetes by the year 2025,
strengthening health system competence particularly
primary health care to address major NCDs, and empower-
ing communities and individuals to self-care. Moreover,
the plan envisages the adoption of the WHO Package
of Essential NCD (PEN) guidelines to screen, diagnose,
treat, and refer DMT2 at village, primary health care center
(PHCC), and hospital levels. The plan emphasizes on
development and implementation of well-structured
media campaigns outlining dose, medium and timing of
information on NCDs to raise awareness on diabetes, as
well as the establishment of baseline information by
conducting a burden of disease study including diabetes.
At the moment, the government has included medicines
of 12 NCDs in the list of essential drugs that are dis-
tributed free of charge (49).
Access to treatment and medications
Few studies have examined access to essential drugs for
diabetes in Nepal. Upadhya et al. in 2007 reported that
out of 685 total drugs prescribed at the hospital, 314
(45.8%) were prescribed for treatment of diabetes. Among
them, biguanides accounted for 51.3%, followed by
sulfonylureas (35.4%), insulin (8.0%), thiazolidinediones
(4.8%), meglitinides, and alpha glucosidase inhibitors
(0.3%) (39). Metformin, being cheap (and affordable),
was the most commonly prescribed drug; 56% of urban
patients were treated with sulphonylureas and 46% of
rural patients with metformin (33). Essential diabetes
drugs such as insulin, metformin, glibenclamide, prota-
mine zinc insulin, and glipizide are included in the
national drug list to which all publicly insured patients
have access (55).
Challenges in diabetes management
Knowledge, attitude, and practice towards diabetes
Patients’ lack of knowledge and attitude towards diabetes
care can hinder their ability to manage their disease.
Published studies on DMT2 knowledge, attitude, and
practice (KAP) showed that there is a poor level of KAP
about diabetes in Nepal. Attitude was defined as the
perception of responsibility towards the disease, and
practice was measured by assessing perception of adher-
ence to diabetes self-care recommendations. A 2015 study
of 244 diabetes patients in urban Nepal reported that
21.3% had highly insufficient knowledge, 22.5% had
insufficient knowledge of diabetes, and 28.3% had poor
attitudes (51). Similarly, the level of practice score was
also poor at 29.1%. This shows that the potential diabetes-
related literacy was low. Another study conducted in 2014
in a tertiary-level care hospital of urban Nepal showed
that half of all 385 DMT2 patients had poor knowledge
level about diabetes (48). Upadhya et al. noted a lack of
awareness of diabetes even in patients attending hospital
in western Nepal who had had the disease for a long time
(41). Likewise, a hospital-based study in 2006 found that
only few patients with diabetes had good knowledge of
causes, curability, treatment modalities, diet, and other
aspects of DMT2 (36).
Coverage of services
Nepal has a pluralistic health system with different health
care facilities, including public and private (56). Public or
the government health facilities have a network of sub-
health posts, health posts, PHCCs, and district hospitals.
Although free health care services are available through
government health facilities, the national priority in
health care is still the prevention and control of commu-
nicable diseases, and maternal and child health services
(19). This means the current health care system is not
optimally equipped to deal with the double burden of
dealing with the ‘old’ low-income country diseases as well
as the new challenges brought on by diabetes and other
NCDs. Diabetes management requires long-term follow-
up with continuous access to medication and specialist
care; however, diabetes care is not a priority for many
health care staff. There is no routine measurement of
blood glucose level as most of the reliable government-
owned laboratories are located in the capital city (50).
PHCCs often lack blood testing equipment, essential
drugs, and diabetes specialists. One study found expired
drugs in district hospitals and PHCCs especially in
mountain districts as well as these facilities running out
of supplies all together (28). Private health facilities, on
the other hand, operate in a largely unregulated market
(57). The private share of total health expenditure in
Nepal is 70%, of which about 85% comes from out-of-
pocket payments, indicating a significant involvement of
private facilities in health provision (58). It is clear that
health care costs put a heavy burden on the poor
jeopardizing their access to the health system, as they
cannot afford private health care.
Moreover, management of DMT2 and its complica-
tions is a formidable challenge to the government owing
to lack of appropriate infrastructure and financing
scheme required to provide diabetes management ser-
vices, and inadequate essential drugs coverage (28). There
is a lack of government support or subsidy that might
result in unaffordable costs. There is inconsistent practice
and limited consultations concerning diabetes diagnosis
and management among health care providers in Nepal
(50). The health system is further moderated by lack
of access to a complete multidisciplinary diabetes health
care system, lack of centralized data system, lack of quality
scientific research in diabetes, and lack of post-graduate
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courses in diabetes (29). Although primary health
care is the backbone of health service delivery, this level
of health care does not have preventive and curative
services for NCDs. At present, the majority of NCDs
services are provided by tertiary-level specialist health
institutions, non-government organizations (NGOs), and
private sectors, most of which are clustered in urban
areas. Organizations such as Nepal Diabetes Association
(59) and Astha Nepal (60) are currently organizing public
awareness campaigns on diabetes management through
free health camps, while another national non-profit
network, the Nepal Diabetic Society, is currently working
to provide diabetic care to patients (61).
To date, there is still no national screening and pre-
vention programme for diabetes albeit the government
has launched the aforementioned Multi-sectoral Action
Plan for the prevention and control of NCDs. Moreover,
the most common diagnostic methods used are based on
glucose criteria such as fasting, postprandial, and ran-
dom blood glucose levels (29). Recently, the HbA1c test
has been endorsed as a diagnostic test in high-income
countries, as a superior alternative to glucose-based criteria.
There is still controversy about implementation of
HbA1c criteria in Nepal due to lack of standardization
of the HbA1c measurement methodology and high cost.
There are only a few reliable laboratories for glucose
measurement and most of these are in the capital and
affected by lack of quality control (50).
Discussion
This systematic review is the first comprehensive analysis
on prevalence, risk factors, cost, complications, treat-
ment, and management of diabetes in Nepal to date. Our
results show that the country is facing an increasing
prevalence of DMT2 and its complications. Moreover,
there is marked countrywide variation in DMT2 pre-
valence, with one study reporting nearly one in five
affected in urban Nepal (35) and as low as 0.3% in rural
Nepal (34).
According to the Sixth Edition of the IDFAtlas (2013),
the national diabetes prevalence of Nepal was 4.5% of the
adult population between 20 and 79 years of age (16). The
2015 edition of the IDF Atlas, which was published after
we completed our study, updated the national estimate
to 3.3% (62). The difference in prevalence estimates in
different settings could be due to differences in which the
analytic populations were defined. For instance, the IDF
estimate takes into account both the urban and the rural
populations. Furthermore, the comparison of these fig-
ures should be done with caution due to differences in
methodology such as different diagnostic criteria used,
different methods adopted, how representative samples
are, and the varying time periods in which the studies have
been performed.
In addition, there is rapid urbanization and the in-
ternal migration from rural to urban areas has contributed
to the increasing rates of DMT2 (15). Despite an increased
burden of disease, there has been minimal effort with
regard to its prevention and control in Nepal. Meanwhile,
the health care system of Nepal is faced with profound
challenges including inequity in health care access, scarcity
of resources, insufficient and untrained human resources,
and financial sustainability (50, 63). Therefore, there is an
immediate need to develop a comprehensive and inte-
grated strategy involving planning, action, and implemen-
tation from the government and all stakeholders to
address the burden of diabetes and control its modifiable
risk factors. The strategic plan should focus on building
and strengthening the primary health care network with
an emphasis on disease screening, prevention, risk-factor
control, and health promotion.
Our review found that patients’ lack of knowledge
about diabetes care limiting patients’ ability to improve
diabetes control through self-management (41, 48, 51).
There is also lack of public awareness regarding diabetes
especially in remote places where medical services are
poor (31). Therefore, Nepal needs to encompass strate-
gies to reach out to the general population to spread
awareness of the disease and its complications as well as
educate and reach out to diabetes patients to improve
outcomes. Educational programmes must be simulta-
neously planned to educate and sensitize various stake-
holders in diabetes management.
The economic burden of diabetes is enormous (47).
Diabetes is costly because of its chronic nature, the
severity of its complications, and the modalities required
to control them. Consequently, people have frequent and
intensive encounters with the health system such as
higher use of hospital inpatient care, outpatient visits,
emergency visits, and prescription drugs. Moreover, the
out-of-pocket expenses associated with diabetes remain a
barrier to the prevention of diabetes-related complica-
tions in Nepal. As a result, diabetic patients tend to forgo
appropriate management due to unaffordable cost of the
treatment (41). This calls for more innovative ways of
financing health care for chronic NCDs in Nepal. There
is also a great variation in cost of prescription drugs used
to treat diabetes in Nepal, as found in India (64) and
elsewhere (65). One tool to decrease the prescription cost
is to prescribe less-expensive trade names provided that
the quality of the alternative is good. People with diabetes
may sometimes need to take two or three different pills
at a time. In this case, combination medications  one
tablet that contains two or more types of medications
combined  may also offer substantially more benefits,
help increasing compliance and, depending on the market
price, potentially even be cost saving (66).
Studies focusing on access to diabetes care and treat-
ment are very limited in Nepal. However, one study
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showed that patients’ adherence to diabetes care and
treatment was higher among those who were nearer to
hospital (48). Patients who were nearer had more frequent
visits to the health care provider, with better follow-up
than those who were far. Thus diabetes care and treatment
can be affected by the availability and cost of screening
tools, especially among less informed populations (38).
Furthermore, in Nepal the availability of free essential
medicines, including diabetes was poor in rural public
hospitals (28). There was also variation in prices of
medications in urban and rural areas, which might result
in poor adherence to diabetes medications (33, 55).
Policymakers should take a broader view that encom-
passes barriers to access to care and treatment. Screening
of those at increased risk and treatment of symptomatic
patients should be in place in all health care settings.
Health systems need to guarantee equitable access to
medicines and technologies, which are of assured quality,
safety, efficacy, and cost-effectiveness and ensure that
these are used in an evidence-based and cost-effective
manner (67).
The high levels of illness associated with diabetes and
other NCDs have compelled the Government of Nepal to
take actions on NCDs or make them a priority. The
Multi-sectoral Action Plan on the Prevention and Con-
trol of NCDs 20142020 (26) offers opportunities for
improving care for diabetes through provisions at the
primary levels of health care. The government’s initia-
tive of including NCDs drugs (68) and more recently
increasing the types of NCDs drugs on the free essential
drugs list (69) is one of the important steps to integration
at primary health care level to deliver health services cost-
effectively and efficiently. Moreover, the government has
recently drafted the New National Health Sector Pro-
gramme III for the period 20152020, which focuses on
strengthening the primary care system through early
treatment of NCDs, including diabetes in both urban
and rural settings. Despite this, recent initiative chal-
lenges remain. The growing problem of NCDs including
diabetes requires the input and influence of all sectors
of societies, including local communities, who play an
enormous role in bringing changes in attitudes towards
health and lifestyle (70). However, there is lack of
experience with community-based prevention for diabetes
in the policy. Health care in general and diabetes in
particular are very heavily dependent on adequate infra-
structure and funding. Government funding for preven-
tive health programmes remains too low to effectively
respond to the growing burden of diabetes. Innovative
financing mechanisms should be explored for generating
funds for diabetes prevention and control.
Our study is limited to the selected database source
and English-language literature, and this might have
missed some relevant articles. Most of the available
diabetes studies in Nepal were institution-based and
urban-focused, leaving a rural research information gap.
Moreover, our study included only those studies that
were available via electronic media, which could have
resulted in the exclusion of studies available in a paper-
based format. Nevertheless, with consideration of these
limitations, this review provides a better understanding of
prevalence, cost, and treatment of DMT2 and its
complications in Nepal and identifies the challenges to
be addressed to contain the epidemic.
Conclusions
DMT2 is emerging as a major health care problem in
Nepal, with rising prevalence and its complications
especially in urban populations. Diabetes prevalence was
associated with various modifiable and non-modifiable
risk factors. Nepal faces several challenges in diabetes
management, including limited health care facilities, high
cost of treatment, lack of disease awareness among
patients, and lack of specific guidelines for the prevention
and treatment of diabetes. Diabetes treatment and pre-
vention efforts were further impeded by the country’s
health system that places a higher priority on communic-
able diseases and maternal and child health services and
by a private health system focused on curative medicine.
There is an urgent need to strengthen the health system so
as to enable it to effectively face the challenges posed by
diabetes and other NCDs. Preventive strategies must take
into account the growing prevalence of risk factors
associated to these diseases. Given the magnitude and
complexity of the diabetes burden, there is an immediate
need for a broad-based approach, and involvement of
relevant stakeholders from the government, civil society,
and the private sector for early detection and primary and
secondary prevention of diabetes and its complications.
The government should develop a comprehensive action
plan to tackle diabetes and other NCDs with clear
responsibilities, a monitoring plan backed by the neces-
sary funds for public awareness about risk reduction
behaviours, and availability of essential medicines to all
sectors of community.
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Paper context
Diabetes mellitus type 2 has emerged as a major health care
problem in Nepal. This low-income country faces several
challenges in diabetes management due to a rising prevalence
and its complications, cost of treatment, limited health care
facilities, lack of disease awareness among patients, and lack of
specific guidelines for the prevention and treatment of diabetes.
The government should develop a comprehensive plan to
tackle diabetes and other non-communicable diseases sup-
ported by appropriate health infrastructure and funding.
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